ICCS 2019 -- Multiple Myeloma (MM) is a cancer formed by malignant plasma cells (PC). Many MM patients are achieving complete remission with advancement in cancer therapies. As a result, quantification of measurable/minimal residual disease (MRD) is becoming increasingly important as an independent predictor of progression-free and overall survival.

Technology has forever transformed the entire healthcare continuum and has ushered in new and revolutionary ways to ensure patient and consumer safety. It has also enabled organizations to achieve higher levels of insight, quality and efficiencies by driving down operational costs and rendering information in meaningful ways.

Running a HABP/VABP trial is inherently difficult but with regulatory incentives, a well-defined study design, effective communications and strong relationships between the sites and study support staff, it is possible to optimize studies and reach the market with novel HABP/VABP treatments for patients in need.

ConSPIC 2019 -- Envision dedicating fifteen years to a critical interest and emptying staggering amount of funds into it, at the same time confronting a disappointment rate of 95 percent. Today's medications go to the business sector after an extensive and very costly process of drug development. It takes anywhere in the range of 10 to 15 years.

This white paper discusses virtual mapping of natural histories, the application of predictive modeling to better understand comorbidities and disease progressions as well as linkage to longitudinal real-world data sets.

Following a successful sponsor/CRO partnership in which Covance supported a large sponsor's reimbursement call center, a solid partnership had formed, founded on trust and a shared culture. The sponsor expanded this partnership with Covance with the desire to seamlessly transition another reimbursement support program from their current vendor.

The Labcorp integrated drug safety solution incorporates a comprehensive set of pharmacovigilance (PV) services across all aspects of the product lifecycle through our state-of-the-art technology platform and streamlined processes.

Overcome the unique challenges of late-phase product development and generate the right data to support your products' objective. Products in late-phase development have complex needs and demands. Programs at this phase support new indications, value communication, adherence strategies, safety and efficacy and more.

Clinical trials are becoming increasingly complex and competitive, so attracting the best investigator sites to participate in a trial is a crucial step in meeting patient enrollment targets. Learn more about how investigator preference can help meet trial recruitment milestones.